Ritonavir: Clinical Trials

604 trials of Ritonavir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

474 completed, 55 terminated, 43 unknown, 18 withdrawn. 205 Phase 1, 167 Phase 2, 110 Phase 3, 89 Phase 4, 38 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 1205Completed 180, Terminated 13, Unknown 5, Recruiting 4, Withdrawn 2, Suspended 1
Phase 2167Completed 125, Terminated 17, Unknown 11, Withdrawn 8, Recruiting 5, Active not recruiting 1
Phase 3110Completed 80, Terminated 11, Unknown 11, Withdrawn 5, Recruiting 2, Not yet recruiting 1
Phase 489Completed 63, Unknown 12, Terminated 11, Withdrawn 2, Recruiting 1
Not applicable38Completed 24, Unknown 6, Terminated 5, Withdrawn 2, Not yet recruiting 1
Early Phase 12Completed 1, Unknown 1

Follow Ritonavir: new trials by email Literature Review of Ritonavir trials Research Report on Ritonavir

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa
Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC) - HIV Infection
Phase 3Not yet recruitingUniversity College, London8002026-11-012026-08-28
STARLITE for Unresectable High-Grade Gliomas
Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine - High Grade Glioma
Phase 1RecruitingUniversity of Miami242025-04-152026-06-25
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
SHR-A1811, Ritonavir, Itraconazole - Advanced Breast Cancer
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.172025-02-172026-06-04
Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV
Gammora® - HIV Seropositivity
Phase 2Active not recruitingFederal University of São Paulo402025-01-012026-06-01
Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients
combination therapy, SOC - COVID-19, SARS-CoV-2
Not applicableNot yet recruitingNational Taiwan University Hospital402024-09-212024-09-25
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
F/TAF (High Dose Tablet), F/TAF (Low Dose Tablet), F/TAF (Lowest Dose Tablet) - HIV-1-infection
Phase 4RecruitingGilead Sciences3502024-08-272026-11-06
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DB-1311, Lopinavir and Ritonavir Tablets, itraconazole - Advanced Solid Tumors
Phase 1 / Phase 2RecruitingDualityBio Inc.8622023-08-172026-10-21
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
Paxlovid, Ritonavir, Nirmatrelvir-matching placebo - Long COVID-19, Long COVID
Phase 2CompletedKanecia Obie Zimmerman9642023-07-262026-03-27
Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants
GST-HG171/Ritonavir, Itraconazole - Healthy Participant
Phase 1CompletedFujian Akeylink Biotechnology Co., Ltd.122023-05-122023-10-17
Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants
GST-HG171/ritonavir, ritonavir - COVID-19 Respiratory Infection
Phase 1UnknownFujian Akeylink Biotechnology Co., Ltd.182023-05-042023-10-16
ImPROving Quality of LIFe in the Long COVID Patient
Nirmatrelvir/ritonavir, Placebo/ritonavir - Post-COVID-19 Syndrome, Long COVID
Phase 2CompletedKarolinska Institutet2192023-05-012024-12-04
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial
Paxlovid 5 days, Paxlovid 10 days, Veklury - COVID-19, Immunodeficiency
Phase 2RecruitingANRS, Emerging Infectious Diseases2562023-04-272026-10-19
A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.
Nirmatrelvir, Ritonavir, Placebo - Long COVID
Phase 2CompletedHarlan M Krumholz1002023-04-142024-12-02
Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects
SIM0417/Ritonavir - Elder
Phase 1UnknownJiangsu Simcere Pharmaceutical Co., Ltd.202023-04-072023-04-24
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
Relugolix Pill, Ritonavir, Itraconazole - Prostate Cancer, Prostate Cancer Metastatic
Phase 1TerminatedUniversity of Chicago602023-02-132024-09-19
Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects
ASC11 tablets, Placebo, RTV tablets - Healthy, COVID-19
Phase 1CompletedAscletis Pharmaceuticals Co., Ltd.722023-01-132024-11-13
Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants
Cohort 1: SIM0417/ritonavir and itraconazole, Cohort 2: SIM0417/ritonavir and rifampicin, Cohort 3: SIM0417/ritonavir and midazolam - Healthy Volunteers
Phase 1CompletedJiangsu Simcere Pharmaceutical Co., Ltd.362022-12-292023-02-21
Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19
GST-HG171/Ritonavir, Placebo - COVID-19 Pneumonia
Phase 2 / Phase 3CompletedFujian Akeylink Biotechnology Co., Ltd.12462022-12-192023-10-12
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
Phase 2WithdrawnPfizer2022-12-132023-03-01
A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women
nirmatrelvir, ritonavir - Healthy Participants
Phase 1CompletedPfizer82022-12-122026-05-01

Showing 20 of 604. Sign in to see all of them.

Conditions studied

HIV Infections (251)  ·  Acquired Immunodeficiency Syndrome (89)  ·  Hepatitis C (40)  ·  COVID-19 (39)  ·  Infections (30)  ·  Hepatitis C, Chronic (26)  ·  Tuberculosis (8)  ·  Coronavirus Infections (7)  ·  Lipodystrophy (5)  ·  Severe Acute Respiratory Syndrome (5)  ·  Virus Diseases (5)  ·  Breast Feeding (4)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Hepatitis D (4)  ·  Immunologic Deficiency Syndromes (4)

Sponsors

Boehringer Ingelheim (56)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (48)  ·  Hoffmann-La Roche (35)  ·  ViiV Healthcare (26)  ·  Bristol-Myers Squibb (23)  ·  Abbott (19)  ·  GlaxoSmithKline (16)  ·  Pfizer (15)  ·  Merck Sharp & Dohme LLC (13)  ·  Gilead Sciences (12)  ·  Tibotec Pharmaceuticals, Ireland (12)  ·  ANRS, Emerging Infectious Diseases (11)  ·  The HIV Netherlands Australia Thailand Research Collaboration (11)  ·  French National Agency for Research on AIDS and Viral Hepatitis (10)  ·  AbbVie (9)

Countries

United States (273)  ·  Spain (67)  ·  Puerto Rico (63)  ·  France (60)  ·  United Kingdom (56)  ·  Germany (54)  ·  Italy (47)  ·  Canada (43)  ·  Thailand (38)  ·  Brazil (32)  ·  South Africa (32)  ·  Argentina (31)  ·  China (28)  ·  Belgium (26)  ·  Australia (24)

Top investigators

Huoling Tang, PhD (5)  ·  Kiat Ruxrungtham, MD (5)  ·  Mikhail Samsonov (5)  ·  Daniel Cohen, MD (3)

Results publications

PMID 40592258, PMID 33901188, PMID 34473343, PMID 37231296, PMID 15687448, PMID 16148846, PMID 18090046, PMID 20074791, PMID 25109510, PMID 25904376, PMID 26797215, PMID 26902761, PMID 29767684, PMID 35179037, PMID 37354048, PMID 10659875, PMID 10954886, PMID 11023461, PMID 11372025, PMID 11399973, PMID 11840078, PMID 11880966, PMID 11927734, PMID 11964551, PMID 11980557, PMID 12195349, PMID 14668455, PMID 14668456, PMID 15002082, PMID 15031785, PMID 15060509, PMID 15090769, PMID 15097312, PMID 15155205, PMID 15187476, PMID 15199325, PMID 15295692, PMID 15316349, PMID 15456093, PMID 15483465, PMID 15668539, PMID 15958837, PMID 16048950, PMID 16048984, PMID 16084849, PMID 16091248, PMID 16103764, PMID 16159645, PMID 16192247, PMID 16220085

NIH funding

2014 (12), 2009 (11), U01AI068636 (7), 2008 (4), 2015 (2), 2023 (2), K23AI074390 (2), 2004 (1), 2005 (1), 2017 (1), 2019 (1), K23AI070078 (1), K23AI077355 (1), K23AI093156 (1), R01AI083036 (1)